Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Top Research Reports For Costco, Exxon & Bristol-Myers

Published 10/06/2016, 01:26 AM
Updated 07/09/2023, 06:31 AM

Thursday, October 6, 2016

Today's Research Daily features new research reports on 16 major stocks, including Costco (NASDAQ:COST), ExxonMobil (NYSE:XOM) and Bristol-Myers (BMY).

Costco shares have been laggards lately as earnings performance has been weighed down by stiff competition and cautious consumer spending trends. However, the analyst emphasizes that Costco continues to be one of the dominant retail wholesalers based on its breadth and quality of merchandise offered. Also, the company’s diversification strategy acts as a natural hedge against risks that may arise in specific markets. (You can read the full research report on Pepsi here>>)

ExxonMobil shares have outperformed the broader market this year on the back oil's positive momentum, though the stock has lagged oil-ier super majors like Chevron (NYSE:CVX) and the major E&P's. This reflects the oil giant's balanced business mix that make it a relatively defensive oil play; the stock doesn't rise as much as its peers in a rising oil price environment, but it doesn't fall by that much when the commodity is heading south either. With a stable cash position, Exxon Mobil’s balance sheet is one of the best in the industry. Exxon's safe and stable dividend (currently yielding an attractive 3.5%) is another key positive. (You can read the full research report on ExxonMobil here>>)

Bristol-Myers shares have been depressed for some time now and are down 20% year-to-date. The company raised its guidance for 2016 earnings once again, buoyed by strong trends across the business, primarily Opdivo and Eliquis. The analyst likes Bristol-Myers’ efforts to develop its pipeline. It has been working on strengthening its product portfolio as well as its pipeline through acquisitions and deals. Also, Bristol-Myers is working on expanding the label of approved drugs including Opdivo, Orencia and Yervoy. (You can read the full research report on Bristol-Myers here>>)

Other noteworthy reports we are featuring today include Shire (SHPG), Baxter (BAX) and Darden (DRI).

Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>

You can find all of today's stock research reports here>>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

Weyerhaeuser (WY) to Sell North Pacific to One Rock

The Zacks analyst thinks Weyerhaeuser's deal to sell-off its printing papers business will enable the company to focus on its core timber, land, and forest products business.

Carnival (LON:CCL) Posts Strong Q3 Results; Prospects Bright

The Zacks analyst believes that efforts to drive demand and higher revenues aided Carnival to beat on Q3 earnings. The company also upped its earnings outlook on the back of strong booking trends.

Washington Federal (WAFD) Enhances Shareholder Returns

The covering analyst thinks Washington Federal's additional share buyback authorization will enhance shareholder value. However, escalated expenses remain a headwind.

State Street (STT) Hikes Dividend, Growth Looks Impressive

The Zacks analyst thinks State Street is also set to capitalize on growth opportunities based on its sturdy capital position.

Rare Disease Portfolio to Boost Shire (SHPG), Risks Remain

The covering analyst thinks that Shire's rare disease portfolio coupled with recent acquisitions should propel the company's growth prospects further. However, generic competition remains a concern.

Marathon Petroleum's (NYSE:MPC) Scale Advantage to Fuel Growth

The covering analyst likes Marathon Petroleum for its scale advantage, impressive asset quality and extensive midstream/retail network.

Baxter (BAX) Poised on New Launches, Cyclophosphamide Woes Hurt

The Zacks analyst think Baxter will gain from new launches like intravenous nutrition product NUMETA G13E. Lower cyclophosphamide sales will hurt the Integrated Pharmacy Solutions franchise business

New Upgrades

Darden (DRI) Poised for Growth Post Q1 Earnings

The Zacks analyst remains upbeat on Darden post its Q1 earnings performance. Sales initiatives like menu innovation, technology-driven moves along with efforts to curtail costs should drive growth.

Omnicom (OMC) Shows Promise for Healthy Long-Term Growth

The Zacks analyst thinks increasing demand for media services, speedy growth of technologies, massive proliferation of channels and strategic acquisitions will improve the Omnicom's top line

CarMax (NYSE:KMX) Gains from Store Expansion, Share Buyback

According to the covering analyst, CarMax's focus on the used-vehicle market, aggressive store-expansion and share repurchases should help it outperform peers.

New Downgrades

Weak End-Markets Dampen ABB Ltd.'s (ABB) Growth Prospects

According to the Zacks analyst, weak end markets and FX headwinds will continue to offset gains from ABB's "Next Level Strategy", lucrative partnership deals & infrastructure market stronghold.

MarketAxess (MKTX) Hurt by Rising Expenses, High Competition

The covering analyst believes that rising expenses, intense competition due to increased market consolidation and stringent regulations are some of the headwinds faced by the company.

Analog Devices (ADI) Hit by Sluggishness in Consumer Market

The Zacks analyst believes that though Analog Devices' strength in the industrial, auto and communication markets is a positive, it is largely offset by significant weakness in the consumer business.



EXXON MOBIL CRP (XOM): Free Stock Analysis Report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

DARDEN RESTRNT (DRI): Free Stock Analysis Report

COSTCO WHOLE CP (COST): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

BAXTER INTL (BAX): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.